What are the key recommendations of the 2024 Clinical Practice Guidelines for the management of acute ischemic stroke and intracerebral hemorrhage in the Philippines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Practice Guidelines on the Management of Acute Ischemic Stroke and Intracerebral Hemorrhage in the Philippines 2024

Note: The provided evidence does not contain the specific 2024 Philippine Clinical Practice Guidelines requested. However, based on the most recent international guidelines and Philippine stroke care context, here is a synthesis of key management recommendations:

Acute Ischemic Stroke Management

Thrombolytic Therapy

Intravenous thrombolysis remains the cornerstone of acute ischemic stroke treatment when administered within the appropriate time window. Blood pressure must be maintained below 185/110 mmHg before treatment and below 180/105 mmHg for 24 hours post-thrombolysis 1.

Key parameters:

  • Do not initiate anticoagulant or antiplatelet therapy within 24 hours of IV rtPA 1
  • Target modest BP reductions of approximately 15% within 24 hours for patients not receiving reperfusion therapy when SBP ≥220 mmHg or DBP ≥120 mmHg 2

Antiplatelet Therapy

Administer aspirin 325 mg orally within 24-48 hours after stroke onset for patients not receiving thrombolysis 1. This provides modest but statistically significant reduction in mortality and unfavorable outcomes, primarily through prevention of early recurrent stroke 1.

Critical restrictions:

  • Aspirin is not a substitute for IV rtPA 1
  • Do not give aspirin or other antiplatelet agents within 24 hours of thrombolysis 1

Anticoagulation

Urgent anticoagulation is not recommended for preventing early recurrent stroke, halting neurological worsening, or improving acute outcomes 1. This applies even to patients with cardioembolic sources, as early anticoagulation increases bleeding risk without reducing early recurrent stroke 1.

Intracerebral Hemorrhage Management

Blood Pressure Control

Rapidly reduce systolic blood pressure to approximately 140 mmHg in acute ICH, while avoiding overshoot, large variability, and excessive early declines 3, 2. This aggressive early BP reduction is critical as hematoma expansion commonly occurs within the first hours and strongly predicts mortality 4.

Specific targets:

  • Acute phase: SBP target ~140 mmHg 2
  • Long-term: BP <130/80 mmHg 2
  • Use calcium channel blockers for acute parenteral therapy 2

Time-Sensitive Interventions

Implement bundled care pathways focused on limiting hematoma expansion within the first hours 4, 5. Priority interventions include:

  • Rapid neuroimaging
  • Controlled BP reduction
  • Timely anticoagulation reversal
  • Seizure management when indicated
  • Prompt neurosurgical consultation 4

Philippine Context Considerations

The Philippines faces significant stroke care gaps that impact guideline implementation 6:

Current Challenges

  • Thrombolysis rate improved to 11% in 2021 (up from 1.4% in 2014-2016) 6
  • Government hospitals achieve 7.4% thrombolysis rate vs 4.8% in private hospitals due to government subsidy 6
  • Mechanical thrombectomy remains extremely low at 0.4% due to cost 6
  • Limited neurologists, CT scan machines, and stroke-trained health workers 6

Practical Adaptations

Non-neurologists can be trained to deliver acute stroke care in areas with limited specialist availability 6. Government insurance coverage (PhilHealth) requires upgrading to adequately cover reperfusion therapies 6.

Secondary Prevention

Long-term Blood Pressure Management

Target BP <130/80 mmHg for chronic management after both ischemic stroke and ICH 2. Use thiazide diuretics, ACE inhibitors, or angiotensin receptor blockers as foundational therapy 2.

Antiplatelet Therapy

Continue long-term antiplatelet therapy for ischemic stroke prevention, with specific agent selection based on stroke mechanism and patient factors 1.

Critical Pitfalls to Avoid

  • Never delay thrombolysis to administer aspirin - aspirin can wait 24 hours 1
  • Never give anticoagulants or antiplatelets within 24 hours of rtPA - this significantly increases hemorrhagic complications 1
  • Never use urgent anticoagulation to prevent early stroke recurrence - it doesn't work and increases bleeding 1
  • Never delay ICH blood pressure reduction - hematoma expansion occurs early and determines outcome 4, 5
  • Avoid excessive BP lowering in acute ischemic stroke without reperfusion therapy unless severely elevated 2

References

Related Questions

How should new‑onset drooling that began after the first three months post‑stroke be managed?
What are the recommended intravenous and oral antihypertensive agents for controlling blood pressure in a patient with acute intracerebral hemorrhage?
What antihypertensive medication regimen is recommended for a patient after a stroke to achieve target blood pressure control?
Can an intracerebral hemorrhage cause acute hypertension?
What muscle relaxant and dosing regimen is appropriate for a post‑stroke patient experiencing painful muscle spasticity?
Do men with a small penis have the same risk of penile fracture as men with normal or large penis size?
What is the recommended treatment for progressive macular hypomelanosis?
Could Bumex (furosemide) cause severe hyponatremia and elevated urine sodium?
Do distal femur fractures require traction?
Why is a Thomas splint not appropriate for distal femur fractures?
Are transient peripheral visual disturbances (dark shadow-like shapes and brief flashes of bright lights) normal in the late second or third trimester of pregnancy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.